Hematology

Authors acknowledge that both the 2022 World Health Organization and International Consensus Classification myelodysplastic syndrome criteria sets have value, while sorting out their similarities and differences.

The FDA has approved axatilimab-csfr (Niktimvo) for treating adults and children with chronic graft-versus-host disease who have progressed on at least 2 prior treatments.

In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL).

As the treatment landscape for chronic lymphocytic leukemia (CLL) has moved into an era where targeted treatments are a mainstay of treatment, new opportunities to tailor therapy have emerged.

Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.

A systematic analysis that reviewed screening for sickle cell retinopathy in patients with sickle cell disease (SCD) underscores the importance of advanced imaging measures and further research on screening implementation methods.

Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and relapse-free survival.

Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs).

Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).

Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.

A new study suggests inhibiting ActivinA might improve the efficacy of chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL).

Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis, regardless of whether the patient had a matched or unmatched donor.

This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.

When the mercury outside ascends too high early in pregnancy, the risk of pediatric acute lymphoblastic leukemia may rise as well; results also show greater impacts on Latino populations.

This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).

The phase 3, international, open-label, single-group XTEND-Kids study concluded that children with severe hemophilia A younger than 12 years benefited from treatment with efanesoctocog alfa prophylaxis.

The panelists provide their final thoughts, highlighting financial considerations in PNH treatment.

Barriers to care and treatment adherence for patients diagnosed with PNH is discussed.

Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, explains the design and objectives of the phase 2 CAPTIVATE study comparing ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL).

The social determinants of health (SDOH) that need to be tackled most urgently when it comes to which patients with large B-cell lymphoma (LBCL) do and do not receive chimeric antigen receptor T-cell therapy (CAR T) are age, sex, income, and race/ethnicity.

This new study evaluates the efficacy of monotherapies and venetoclax combination therapies in different T-cell acute lymphoblastic leukemia (ALL) cell lines.

The findings show most patients with low-risk myelodysplastic syndrome (MDS) will die before progression.

Researchers of a new study explore what areas of chronic lymphocytic leukemia (CLL) treatment and care are important to patients and identify key areas for improvement.

Peer and survivorship support are lacking for patients living with multiple myeloma, leading investigators to evaluate a group-focused multidisciplinary intervention that encompassed physical and mental activities.

In this interview from our coverage of the European Hematology Association 2024 Congress, we spoke with Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, executive vice president and chief medical officer of the CLL Society and himself a survivor of chronic lymphocytic leukemia (CLL), to discuss treatment advancements and the importance of addressing both unmet needs and patient treatment preferences.

Patients with myelodysplastic syndrome (MDS) in the treatment arm were more likely to achieve transfusion independence, but the difference vs placebo was not statistically significant.

A post-hoc analysis showed that zanubrutinib resulted in fewer adverse events compared with ibrutinib.

Patient outcomes in this trial were compared between the regimens of lenalidomide, bortezomib, and dexamethasone and daratumumab, lenalidomide, bortezomib, and dexamethasone for use against multiple myeloma (MM).

Researchers collected feedback from 20 clinicians implementing a telehealth serious illness conversation (SIC) with their patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

In this new analysis, investigators review the late adverse events associated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.